204 related articles for article (PubMed ID: 35860247)
21. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen.
Alawad AS; Auh S; Suarez D; Ghany MG
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):700-709.e3. PubMed ID: 31323381
[TBL] [Abstract][Full Text] [Related]
22. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients.
Wang WX; Jia R; Jin XY; Li X; Zhou SN; Zhang XN; Zhou CB; Wang FS; Fu J
Front Immunol; 2023; 14():1121778. PubMed ID: 36756119
[TBL] [Abstract][Full Text] [Related]
23. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
Al Mahtab M; Akbar SMF; Aguilar JC; Guillen G; Penton E; Tuero A; Yoshida O; Hiasa Y; Onji M
PLoS One; 2018; 13(8):e0201236. PubMed ID: 30133478
[TBL] [Abstract][Full Text] [Related]
24. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B.
Jeng WJ; Papatheodoridis GV; Lok ASF
Lancet; 2023 Mar; 401(10381):1039-1052. PubMed ID: 36774930
[TBL] [Abstract][Full Text] [Related]
26. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
[No Abstract] [Full Text] [Related]
27. Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis.
Yao Y; Zhang J; Li X; Zao X; Cao X; Chen G; Ye Y
Front Public Health; 2022; 10():1037527. PubMed ID: 36407996
[TBL] [Abstract][Full Text] [Related]
28. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens.
Pan CQ; Li MH; Yi W; Zhang L; Lu Y; Hao HX; Wan G; Cao WH; Wang XY; Ran CP; Shen G; Wu SL; Chang M; Gao YJ; Xie Y
Liver Int; 2021 Jul; 41(7):1498-1508. PubMed ID: 33486874
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
Chen H; Ding X; Liao G; Xia M; Ren Z; Fan R; Peng J
J Viral Hepat; 2021 Aug; 28(8):1121-1129. PubMed ID: 33899998
[TBL] [Abstract][Full Text] [Related]
32. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
33. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy.
Li MH; Yi W; Zhang L; Lu Y; Lu HH; Shen G; Wu SL; Hao HX; Gao YJ; Chang M; Liu RY; Hu LP; Cao WH; Chen QQ; Li JN; Wan G; Xie Y
J Viral Hepat; 2019 Jul; 26 Suppl 1():32-41. PubMed ID: 31380582
[TBL] [Abstract][Full Text] [Related]
34. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
35. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
36. Successful interferon treatment in a patient chronically infected with hepatitis B virus carrying unusual S- (and P-) mutants in the presence of anti-HBs antibodies.
Frider B; Alessio A; Pozzati M; Cuestas ML; Mathet VL; Oubiña JR
Liver Int; 2007 Jun; 27(5):727-30. PubMed ID: 17498261
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
38. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
